Brief: Quince Therapeutics Announces First Patient Dosed In Phase 3 Clinical Trial
25/06/2024 12:02
June 25 (Reuters) - Quince Therapeutics Inc QNCX.O :
* QUINCE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
3
CLINICAL TRIAL OF ERYDEX FOR THE TREATMENT OF
ATAXIA-TELANGIECTASIA
* QUINCE THERAPEUTICS INITIATES PHASE 3 TRIAL OF ERYDEX
* QUINCE EXPECTS PHASE 3 NEAT RESULTS H2 2025
Source text for Eikon: ID:nBw68fGHPa
Further company coverage: QNCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges